Cleveland

DELFI Diagnostics to Highlight Breakthrough Technology and Completed Clinical Study in Lung Cancer Detection

Retrieved on: 
Wednesday, October 4, 2023

BALTIMORE and PALO ALTO, Calif., Oct. 4, 2023 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to detect cancer, announced today that the company will participate in multiple sessions at the HLTH 2023 conference in Las Vegas, Nevada, and the CHEST 2023 Annual Meeting in Honolulu, Hawai'i, both taking place October 8-11, 2023.

Key Points: 
  • DELFI's approach to early cancer detection applies advanced machine learning technology to whole-genome sequencing data to compare an individual's cell-free DNA (cfDNA) patterns and characteristics against populations with and without cancer.
  • An oral presentation at CHEST will highlight new data from the DELFI-L101 Study, "DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study," a prospective, multicenter, case-control study among individuals eligible for lung cancer screening to train and independently validate the blood-based test for early cancer detection.
  • Victor Velculescu, M.D., Ph.D., DELFI Founder and Chief Executive Officer, will deliver a science and technology presentation on the company's lung cancer early detection test.
  • As part of the "Updates in Lung Cancer" session, Peter Mazzone, M.D., MPH, Director of the Lung Cancer Program and Lung Cancer Screening Program for the Respiratory Institute at the Cleveland Clinic and the principal investigator for DELFI's L101 study, will present new data from the study during an oral presentation.

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

Retrieved on: 
Tuesday, October 3, 2023

JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology.

Key Points: 
  • JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology.
  • The clinical study evaluated single and repeat doses of neffy compared to single and repeat doses of approved injection products in healthy subjects.
  • For repeat doses of neffy, mean maximum changes in PD responses for both blood pressure and heart rate were statistically greater than repeat doses of EpiPen.
  • In addition, the PK profile for a second dose of neffy was approximately dose-proportional, unlike EpiPen, where the second dose delivered less incremental epinephrine exposure than the first dose.

Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference

Retrieved on: 
Monday, October 2, 2023

CHESTERBROOK, Pa., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced completion of initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study.

Key Points: 
  • The VOLITION study, a real-world, open-label, multi-site study, assessed the potential impact of OLINVYK on respiratory, gastrointestinal (GI), and cognitive function outcomes in the postoperative setting.
  • “We are pleased to announce completion of the initial analysis of respiratory data from the ~200 patient VOLITION study generated at Cleveland Clinic and Wake Forest Baptist Health,“ said Carrie Bourdow, President and CEO of Trevena.
  • “We are excited to present these new results at the upcoming ASA meeting in October.”
    VOLITION Study Data, Including Continuous Respiratory Monitoring Analysis, to be Presented at ASA in San Francisco from October 13-17, 2023.
  • VOLITION is a real-world, open-label, multi-site, post-approval clinical outcomes study in 203 adult patients undergoing major non-cardiac surgery (197 patients with evaluable respiratory data).

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

Retrieved on: 
Thursday, September 28, 2023

In this long-term open-label safety study, tenapanor showed acceptable tolerability with a safety profile consistent with that reported in the prior studies.

Key Points: 
  • In this long-term open-label safety study, tenapanor showed acceptable tolerability with a safety profile consistent with that reported in the prior studies.
  • “The T3MPO-3 results provide important data on IBSRELA’s safety profile in a longer-term setting,” said David Rosenbaum, Ph.D., chief development officer of Ardelyx.
  • Adults with IBS-C frequently suffer from constipation, abdominal pain, bloating and other symptoms, which has a significant impact on their quality of life.
  • Patients received open-label tenapanor 50 mg twice a day for up to an additional 39 (T3MPO-1) or 26 (T3MPO-2) weeks.

Revolutionary Senior Care Platform Homecare Hub Sets Sights on Expansion, Secures Strategic Seed Funding from Inception Health, Ballad Ventures, CABHI, Blue Lion Global, AARP

Retrieved on: 
Tuesday, September 26, 2023

The oversubscribed $2.5 Million USD round exceeded initial targets, and additional milestone-based funding was also secured.

Key Points: 
  • The oversubscribed $2.5 Million USD round exceeded initial targets, and additional milestone-based funding was also secured.
  • "Homecare Hub is leading the way in closing the gaps for complex hospital discharges.
  • "With Homecare Hub, we're investing in the future of more personalized, high-quality, and affordable care options in both post-acute and long-term care.
  • The Blue Lion Global Fund participated and placed operating partner Matt Atkin to play a hands-on role on at Homecare Hub.

Massive, multi-year transformation of Verizon’s network yields major benefits for customers

Retrieved on: 
Tuesday, September 26, 2023

While this massive undertaking is not over, the results have been unmistakable, with customers using the network in more places in more ways and having a better experience on the Verizon network.

Key Points: 
  • While this massive undertaking is not over, the results have been unmistakable, with customers using the network in more places in more ways and having a better experience on the Verizon network.
  • Redesigning the core of the network to function in a cloud-native environment and introducing advanced technologies such as virtualization , automation and orchestration throughout the network.
  • Home Internet, Business Internet and Private Networks have altered how, when and where customers access the network.
  • While customers are using more data and using it differently, the massive network upgrades have enabled customers to have a markedly better experience than ever before.

Kampinski & Roberts Obtains $7.625 Million Verdict in Medical Malpractice Case Against Cleveland Clinic

Retrieved on: 
Monday, September 25, 2023

CLEVELAND, Sept. 25, 2023 /PRNewswire/ -- On June 6, 2023, the Ohio law firm of Kampinski & Roberts achieved a legal victory for their clients, Eloise and William Hance, winning a $7,625,000 verdict against the Cleveland Clinic.

Key Points: 
  • CLEVELAND, Sept. 25, 2023 /PRNewswire/ -- On June 6, 2023, the Ohio law firm of Kampinski & Roberts achieved a legal victory for their clients, Eloise and William Hance, winning a $7,625,000 verdict against the Cleveland Clinic.
  • The case was tried by Charles Kampinski and Kristin Roberts and involved medical malpractice committed by neurosurgeons Dr. Iain Kalfas and Dr. Eric Schmidt.
  • Eloise Hance, an active and athletic 68-year-old woman, sought medical help for back pain, leading her to Dr. Kalfas.
  • Despite the verdict, Dr. Kalfas retains his medical license and remains at the Cleveland Clinic.

Realeve Unveils Breakthrough Solution to Treat Central Nervous System Disorders Including Stroke and Cluster Headache; Bypasses Brain’s Natural Barrier to Deliver Therapeutics

Retrieved on: 
Thursday, September 21, 2023

Realeve has also been granted Breakthrough Device designation from the FDA with a goal of obtaining FDA approval and CE Mark to treat cluster headaches in 2024.

Key Points: 
  • Realeve has also been granted Breakthrough Device designation from the FDA with a goal of obtaining FDA approval and CE Mark to treat cluster headaches in 2024.
  • We are also exploring its applications in other central nervous system disease conditions and excited about the potential,” states Dr. Peter Bonutti, founder and president, Realeve.
  • This technology holds promise for addressing conditions like Alzheimer's, tumors, and other central nervous system disorders.
  • The targeted therapy provides both pain relief, and can increase blood flow and medication delivery to the central nervous system.

A Decade of Innovation: SimX Debuts the Virtual Manikin Series for Customizable, True-to-Life Medical Training

Retrieved on: 
Wednesday, September 20, 2023

Currently, the SimX Virtual Manikin Series offers two encounters: one focused on pediatric pathologies and the other on adults with chest pain-related complaints.

Key Points: 
  • Currently, the SimX Virtual Manikin Series offers two encounters: one focused on pediatric pathologies and the other on adults with chest pain-related complaints.
  • More Virtual Manikin subtypes are in development and will be made available on the SimX Marketplace as they are finalized, tested, and integrated into the series.
  • The SimX Virtual Manikin series includes a scenario preset feature where instructors can create and save custom patient findings, diagnoses, vitals, and patient animations.
  • Each Virtual Manikin scenario comes with a handful of preconfigured presets for quick and easy simulation training based on true-to-life patient encounters.

Implicity CEO Selected to Participate in HRX 2023 Panel Discussion on AI & Remote Cardiac Monitoring

Retrieved on: 
Monday, September 18, 2023

CAMBRIDGE, Mass, Sept. 18, 2023 /PRNewswire/ -- Implicity, a leader in remote patient monitoring (RPM) and cardiac data management solutions, announced today that co-founder and CEO Arnaud Rosier, MD, PhD, has been selected to participate in a panel discussion at the upcoming HRX 2023 Digital Health Event in Seattle, WA. The discussion, AI-aided Remote Interventions - Will this Transform Healthcare Delivery & Outcomes, takes place September 22, 2023, at 2:30 pm (PDT).

Key Points: 
  • CAMBRIDGE, Mass, Sept. 18, 2023 /PRNewswire/ -- Implicity , a leader in remote patient monitoring (RPM) and cardiac data management solutions, announced today that co-founder and CEO Arnaud Rosier, MD, PhD, has been selected to participate in a panel discussion at the upcoming HRX 2023 Digital Health Event in Seattle, WA.
  • The discussion, AI-aided Remote Interventions - Will this Transform Healthcare Delivery & Outcomes , takes place September 22, 2023, at 2:30 pm (PDT).
  • As part of the discussion, Dr. Rosier intends to share insights on new international recommendations for remote monitoring of cardiovascular implantable devices (CIED) released at Heart Rhythm 2023 (HRS) .
  • "We recently published groundbreaking data that demonstrated our AI-powered cardiac remote monitoring technology saves lives and significantly improves health outcomes," said Dr. Rosier, electrophysiologist, CEO, and co-founder of Implicity.